NCT00680134

Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis

An Open Label, Multi-center Study To Evaluate The Safety And Efficacy Of Topically Applied An2690 1% And 5% Solutions For The Treatment Of Adult Subjects With Onychomycosis Of The Great Toenail

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine the safety and efficacy of 1% and 5% AN2690 solutions in the treatment of distal, subungual onychomycosis of the great toenail.

Detailed description

The first group of 30 protocol-qualified subjects will be assigned to Treatment Group 1 and given 1% AN2690 Solution. The second group of 30 protocol-qualified subjects will be assigned to Treatment Group 2 and given 5% AN2690 Solution.

Conditions

• Onychomycosis

Interventions

Type	Name	Description
DRUG	AN2690	AN2690 1% Solution, once daily for 180 days
DRUG	AN2690	AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days

Timeline

• Start date: 2006-06-30
• Primary completion: 2007-08-31
• Completion: 2007-08-31
• First posted: 2008-05-19
• Last updated: 2018-02-20

Locations

7 sites across 1 country: United States